Responder and health‐related quality of life analyses in men with lower urinary tract symptoms treated with a fixed‐dose combination of solifenacin and tamsulosin oral‐controlled absorption system: results from the NEPTUNE study

Abstract

In men with LUTS/BPH who have moderate-to-severe storage symptoms and voiding symptoms, the reduction in symptoms with a once-daily FDC of solifenacin and TOCAS was associated with consistent patient-relevant improvements in HRQoL compared with placebo and TOCAS monotherapy.